Ehave is pioneering an evidence-based approach to treatment using medical cannabis to support the emerging industry and to improve patient outcomes through the use of objective, high-quality data.

We believe that the cannabis industry lacks comprehensive data for clinicians to draw from when advising patients on treatment plans, as well as reliable systems to track outcomes. Ehave may enable more accurate and efficient study of cannabis and help establish objective guidelines that clinicians can rely upon when prescribing cannabis therapies.

We Seek to Answer Common Questions and Concerns
  • Is cannabis the right therapeutic to prescribe?
  • What is the most effective strain for a particular condition?
  • What is the appropriate dose or delivery method for a particular condition?
  • How does a clinician compare treatment options?
  • How can clinicians ensure that patients are using the product as prescribed?
  • How do patients know their prescription is working the way its supposed to?
  • Do payors have the right reimbursement criteria?
  • Where should licensed producers concentrate their research and development efforts?

Ehave has entered into a partnership with MedReleaf, Canada’s leading medical cannabis licensed producer, to use the Ehave Platform to advance the study of cannabis. Learn more >>

The Ehave Platform

Some evidence suggest that cannabis may benefit some persons suffering from mental health conditions. However, clinicians are trained to make medical suggestions based on robust clinical data which is lacking in the emerging field of cannabis.

An evidence-based approach is needed to conclusively determine the medical benefits of cannabis – the results of this research may drive clinician and patient adoption of cannabis. Additionally, more research is needed to characterize the compounds found within cannabis that may offer therapeutic benefits – this could maximize the benefits of cannabis while potentially reducing unwanted side effects.

Ehave is proud to offer a mental health informatics platform that seeks to empower patients, clinicians, and researchers with the tools needed to monitor every step of the cannabis treatment life cycle, from diagnosis and treatment planning to outcomes verification.

Platform Core

Ehave offers a powerful set of core features that allow clinicians to manage and communicate with patients, guide diagnosis and treatment, and interpret outcomes data.

 Schedule a Demo

Patient Management
Enables clinicians to create and manage login credentials for each user
Communication Tools
Improve patient engagement with tools that allow for seamless communication with users across desktop computers, tablets, and mobile devices
Analyze patient and clinician-reported outcomes to evaluate treatment progress and to verify outcomes

Ehave Connect

Ehave is proud to offer clinically-validated diagnostic and treatment tools to clinicians via Ehave Connect. We work with trusted third-parties to integrate tools into the Ehave ecosystem so that clinicians can more easily diagnose and treat patients while taking full advantage of all collected data.

  • Ehave seeks to adapt clinically-validated diagnostic and treatment tools for enhanced patient engagement and data modeling.
  • Ehave diagnostic and treatment tools are cross-platform compatible and can be remotely administered.

Conners CBRS™

Conners 3™

Davidson Trauma Scale (DTS™)


Conners is a registered trademark of Multi-Health Systems

Mental Health Conditions and Cannabis

Cannabis is being used to treat a variety of mental health conditions including PTSD, anxiety, depression, and others. While the use of cannabis is becoming more widespread, data supporting its use is extremely limited and potentially biased. A systematic review published in the Journal of the American Medical Association (“JAMA”) in 2015 examined 79 articles focused on cannabis and determined that only four of them had been conducted with a low-risk of bias.

Post-Traumatic Stress Disorder (“PTSD”)

Cannabis has been proposed as a treatment is PTSD. The use of cannabis among patients with PTSD is particularly prevalent among veterans. The clinical evidence regarding the use of cannabis is contradictory. A recent case-control study of 700 veterans found no improvement in PTSD symptoms among cannabis users compared to non-users. An observational study of 2,276 veterans published in 2015 suggests that, not only does cannabis not provide benefits for persons with PTSD, it may be harmful.


Cannabis is being investigated as a treatment for anxiety disorders. A study of 24 patients given CBD (a non-psychoactive constituent of cannabis) reported improvement in anxiety symptoms as compared to a control group given a placebo. However, the study was determined to have a high risk of bias in a review by JAMA. Four other studies have suggested that cannabinoids may improve anxiety symptoms, but all four trials reported these effects as ancillary findings in studies being performed for other purposes. The analysis of cannabis for the treatment of anxiety is further complicated because anxiety is a common side effect of cannabis use.


Cannabis is being investigated for use in patients with depression. A review published in JAMA found that no clinical trials had specifically evaluated the use of cannabis as a treatment for depression – however, depression was included as an outcome measure in five studies performed with other primary objectives. No benefits were reported in any of the studies.

Learn More

Contact us to schedule a demo.